• Type: Third generation cephalosporin
  • Dosage Forms: capsule, oral suspension
  • Dosage Strengths: capsule: 300mg; oral suspension: 125mg/5mL, 250mg/5mL
  • Routes of Administration: PO
  • Common Trade Names: Omnicef

Adult Dosing

  • 600mg/d divided q12-24hrs for 10 days for CAP, chronic bronchitis, acute sinusitis, strep pharyngitis, cellulitis

Pediatric Dosing

  • 14mg/kg/d PO divided q12-24hrs x10 days, max of 600mg/day

Special Populations

  • Pregnancy Rating: B
  • Lactation: Probably safe
  • Renal Dosing
    • Adult: CrCl <30, 300mg q24hrs; CrCl <10, 300mg q48hrs; supplement after HD
    • Pediatric: CrCl <30, 7mg/kg q24, max 300mg/dose; supplement after HD
  • Hepatic dosing not defined


  • Allergy to class/drug

Adverse Reactions


  • Diarrhea
  • Bloody stools which are guiac negative and returns to normal color after cessation[1]


  • Half-life: 100 min
  • Metabolism: Not appreciably metabolized
  • Excretion: Urine (7-25% as unchanged drug)
  • Mechanism of Action: Bactericidal, inhibits bacterial cell wall synthesis

Antibiotic Sensitivities[2]

Group Organism Sensitivity
Gram PositiveStrep. Group A, B, C, GS
Strep. PneumoniaeS
Viridans strepS
Strep. anginosus gpX1
Enterococcus faecalisR
Enterococcus faeciumX1
Staph. EpidermidisI
C. jeikeiumX1
L. monocytogenesR
Gram NegativesN. gonorrhoeaeS
N. meningitidisX1
Moraxella catarrhalisS
H. influenzaeS
E. coliS
Klebsiella spS
E. coli/Klebsiella ESBL+R
E coli/Klebsiella KPC+R
Enterobacter sp, AmpC negR
Enterobacter sp, AmpC posR
Serratia spR
Serratia marcescensX1
Salmonella spS
Shigella spS
Proteus mirabilisS
Proteus vulgarisI
Providencia sp.X1
Morganella sp.R
Citrobacter freundiiR
Citrobacter diversusX1
Citrobacter sp.S
Aeromonas spX1
Acinetobacter sp.X1
Pseudomonas aeruginosaR
Burkholderia cepaciaX1
Stenotrophomonas maltophiliaX1
Yersinia enterocoliticaX1
Francisella tularensisX1
Brucella sp.X1
Legionella sp.R
Pasteurella multocidaS
Haemophilus ducreyiX1
Vibrio vulnificusX1
MiscChlamydophila spX1
Mycoplasm pneumoniaeX1
Rickettsia spX1
Mycobacterium aviumX1
Bacteroides fragilisX1
Prevotella melaninogenicaX1
Clostridium difficileX1
Clostridium (not difficile)X1
Fusobacterium necrophorumX1
Peptostreptococcus sp.X1


  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also


  1. Graves R, Weaver SP. Cefdinir-associated "bloody stools" in an infant. J Am Board Fam Med. 2008;21(3):246-248. doi:10.3122/jabfm.2008.03.070242
  2. Sanford Guide to Antimicrobial Therapy 2014
This article is issued from Wikem. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.